泰诺麦博创新药新替妥终结破伤风防治百年难题

Group 1 - The documentary highlights a revolutionary breakthrough in the field of tetanus prevention, showcasing the innovative monoclonal antibody drug, New Tizhuo (generic name: Staidutata monoclonal antibody injection), developed by Zhuhai Tenomab Pharmaceutical Co., Ltd, which offers a new "Chinese solution" to longstanding clinical challenges in this area [1][2] - Approximately 50 million people in China use tetanus vaccines annually, indicating a significant public health concern, as traditional tetanus treatments derived from horse and human blood have notable safety and accessibility issues [1][2] - The approval of New Tizhuo by the National Medical Products Administration (NMPA) on February 11, 2025, marks a significant advancement in tetanus prevention, allowing for rapid intramuscular injection without the need for skin tests or routine observation [2][3] Group 2 - Traditional tetanus treatments, such as Tetanus Antitoxin (TAT), have a high allergic reaction rate of 5% to 30%, leading to safety concerns and their removal from the WHO's essential medicines list in 1991 [2] - The new drug utilizes fourth-generation monoclonal antibody technology, which has low immunogenicity and a significantly reduced incidence of allergic reactions, addressing the supply challenges of traditional human immunoglobulin [3] - The company emphasizes the importance of source innovation in drug development, highlighting the need for original research and development to meet domestic healthcare needs [3][4]